Clinical and laboratory predictors of lupus nephritis pathological class and induction treatment response: a retrospective cohort study with multivariable predictive modeling

Background/Aim Lupus nephritis (LN) is the most severe visceral manifestation of systemic lupus erythematosus and a leading cause of chronic kidney disease. Renal biopsy remains the reference standard for classifying LN, yet it is invasive, costly, and difficult to repeat. This study aimed to develop interpretable predictive models based on routine clinical and laboratory biomarkers to distinguish proliferative from non-proliferative LN and to predict 6-month complete response (CR) after induction therapy. Methods We retrospectively enrolled 174 patients with biopsy-proven LN diagnosed between January 2021 and August 2024 at two Chinese tertiary centers. Baseline demographics, clinical parameters, autoantibody profiles, and renal histopathology according to the 2018 ISN/RPS classification were collected. Patients were grouped as proliferative LN (classes III, IV, and III/IV+V) or non-proliferative LN (classes II, V, and VI). Univariable and multivariable logistic regression were used to identify independent predictors; model discrimination was quantified with receiver operating characteristic curves and the area under the curve (AUC), and internal validation was performed by bootstrap resampling (1000 resamples) with optimism-corrected performance estimates. Results Overall, 117 patients (67.2%) had proliferative LN and 57 (32.8%) had non-proliferative LN. Proliferative LN was characterized by more hypertension, more severe anemia, lower estimated glomerular filtration rate (eGFR), higher urinary red blood cell count, and higher positivity rates of anti-dsDNA, anti-C1q, anti-nucleosome, anti-histone, and p-ANCA antibodies. Multivariable analysis identified lower eGFR (OR 0.978, 95% CI 0.966–0.989, P<0.001), higher urinary red blood cell count (OR 1.012, 95% CI 1.003–1.021, P = 0.007), higher anti-dsDNA antibody (OR 1.002, 95% CI 1.001–1.003, P = 0.012), and higher anti-C1q antibody (OR 1.047, 95% CI 1.015–1.080, P = 0.003) as independent predictors of proliferative LN. The combined anti-dsDNA/anti-C1q model yielded an AUC of 0.7877. In proliferative LN, higher age, higher baseline eGFR, higher anti-dsDNA antibody, and higher anti-C1q antibody independently predicted 6-month CR, although the anti-dsDNA association was attenuated to borderline significance after adjustment for the histological chronicity index (P = 0.053), whereas the anti-C1q association remained significant (P = 0.012); in non-proliferative LN, only baseline urine protein-to-creatinine ratio was independently predictive. Conclusion Baseline eGFR, urinary red blood cell count, anti-dsDNA antibody, and anti-C1q antibody provide a non-invasive means to estimate the likelihood of proliferative LN and may help prioritize patients for timely renal biopsy; however, given the moderate discrimination of the present models, these markers are intended to complement rather than replace renal biopsy. Anti-C1q antibody additionally predicts short-term induction response (an early, intermediate endpoint) in proliferative LN, whereas anti-dsDNA antibody shows only a possible association with response that requires confirmation in future studies; these markers support their integration into interpretable, data-driven risk-stratification algorithms for personalized management, pending external validation in prospective, multi-center cohorts.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1985368
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and laboratory predictors of lupus nephritis pathological class and induction treatment response: a retrospective cohort study with multivariable predictive modeling

Kaijiang Tang, Zhiming Lin, Ke Hu, Guangting Li
2 links
Frontiers in Immunology
Systemic Lupus Erythematosus Research
article

Clinical and laboratory predictors of lupus nephritis pathological class and induction treatment response: a retrospective cohort study with multivariable predictive modeling

Kaijiang Tang, Zhiming Lin, Ke Hu, Guangting Li
article en

Abstract

Background/Aim Lupus nephritis (LN) is the most severe visceral manifestation of systemic lupus erythematosus and a leading cause of chronic kidney disease. Renal biopsy remains the reference standard for classifying LN, yet it is invasive, costly, and difficult to repeat. This study aimed to develop interpretable predictive models based on routine clinical and laboratory biomarkers to distinguish proliferative from non-proliferative LN and to predict 6-month complete response (CR) after induction therapy. Methods We retrospectively enrolled 174 patients with biopsy-proven LN diagnosed between January 2021 and August 2024 at two Chinese tertiary centers. Baseline demographics, clinical parameters, autoantibody profiles, and renal histopathology according to the 2018 ISN/RPS classification were collected. Patients were grouped as proliferative LN (classes III, IV, and III/IV+V) or non-proliferative LN (classes II, V, and VI). Univariable and multivariable logistic regression were used to identify independent predictors; model discrimination was quantified with receiver operating characteristic curves and the area under the curve (AUC), and internal validation was performed by bootstrap resampling (1000 resamples) with optimism-corrected performance estimates. Results Overall, 117 patients (67.2%) had proliferative LN and 57 (32.8%) had non-proliferative LN. Proliferative LN was characterized by more hypertension, more severe anemia, lower estimated glomerular filtration rate (eGFR), higher urinary red blood cell count, and higher positivity rates of anti-dsDNA, anti-C1q, anti-nucleosome, anti-histone, and p-ANCA antibodies. Multivariable analysis identified lower eGFR (OR 0.978, 95% CI 0.966–0.989, P<0.001), higher urinary red blood cell count (OR 1.012, 95% CI 1.003–1.021, P = 0.007), higher anti-dsDNA antibody (OR 1.002, 95% CI 1.001–1.003, P = 0.012), and higher anti-C1q antibody (OR 1.047, 95% CI 1.015–1.080, P = 0.003) as independent predictors of proliferative LN. The combined anti-dsDNA/anti-C1q model yielded an AUC of 0.7877. In proliferative LN, higher age, higher baseline eGFR, higher anti-dsDNA antibody, and higher anti-C1q antibody independently predicted 6-month CR, although the anti-dsDNA association was attenuated to borderline significance after adjustment for the histological chronicity index (P = 0.053), whereas the anti-C1q association remained significant (P = 0.012); in non-proliferative LN, only baseline urine protein-to-creatinine ratio was independently predictive. Conclusion Baseline eGFR, urinary red blood cell count, anti-dsDNA antibody, and anti-C1q antibody provide a non-invasive means to estimate the likelihood of proliferative LN and may help prioritize patients for timely renal biopsy; however, given the moderate discrimination of the present models, these markers are intended to complement rather than replace renal biopsy. Anti-C1q antibody additionally predicts short-term induction response (an early, intermediate endpoint) in proliferative LN, whereas anti-dsDNA antibody shows only a possible association with response that requires confirmation in future studies; these markers support their integration into interpretable, data-driven risk-stratification algorithms for personalized management, pending external validation in prospective, multi-center cohorts.

Frontiers in ImmunologyVol. 17
Liuzhou Maternal and Child Health Hospital (CN), Liuzhou General Hospital (CN), Fourth Affiliated Hospital of Guangxi Medical University (CN), Third Affiliated Hospital of Sun Yat-sen University (CN)
Liuzhou Science and Technology Project
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon